



Received on 28 April 2020; received in revised form, 04 September 2020; accepted, 11 September 2020; published 01 May 2021

## ANTIHYPERTENSIVE ACTIVITY GUIDED-FRACTIONATION OF *NARDOSTACHYS JATAMANSI*

B. B. Rachotimath<sup>1</sup>, M. S. Gavimath<sup>2</sup> and B. Padmashali<sup>\*1</sup>

Department of Chemistry<sup>1</sup>, School of Basic Sciences, Rani Channamma University, Belagavi - 591156, Karnataka, India.

Department of Rasashastra and Bhaishajya Kalpana<sup>2</sup>, SBSS Krishna Ayurvedic Medical College and Hospital, Sankeshwar - 591313, Karnataka, India.

### Keywords:

*Nardostachys jatamansi*,  
Angiotensin converting enzyme  
(ACE), Hypertension, Extracts,  
Column chromatography

### Correspondence to Author:

**Prof. Basavaraj Padmashali**

Professor,  
Department of Chemistry,  
School of Basic Sciences, Rani  
Channamma University, Belagavi -  
591156, Karnataka, India.

**E-mail:** basavarajpadmashali@yahoo.com

**ABSTRACT:** The present study aimed to examine the anti-hypertensive constituents present in *Nardostachys jatamansi*. Crude solvent extracts (dichloromethane; ethyl acetate; methanol, and water) of this plant rhizomes based on the difference in polarity were prepared and tested for inhibition of angiotensin-converting enzyme (ACE). Preliminary phytochemical analysis showed bioactive compounds such as alkaloids, flavonoids, carbohydrates, triterpenoid, glycosides, saponin, and tannins in different extracts. Ethyl Acetate extract has shown better results with 93% inhibition at 100 µg concentration as compared to other solvent extracts. Fractionation of ethyl acetate extract over silica gel column chromatography with hexane and ethyl acetate under gradient elution resulted in six fractions. However, on purification of the ethyl acetate extract, ACE inhibition activity diminishes with only 19.03 to 47.35% inhibition for the purified fractions. *Nardostachys jatamansi* can be used to treat hypertension-related disorders, and ethyl acetate extract can be further investigated to identify potent molecules that work in a synergistic combination.

**INTRODUCTION:** *Nardostachys jatamansi* (family Valerianaceae) is a perennial herb found in Alpine Himalayas. It is a reputed Ayurvedic herb and have demonstrated hypotensive, hypolipidemic, antimicrobial, antiarrhythmic, hepatoprotective, etc.<sup>1-8</sup> Ethanol extract of the roots of *N. jatamansi* DC was studied for its anticonvulsant activity and neurotoxicity demonstrated a significant increase in the seizure threshold by *N. jatamansi* DC root extract against maximal electroshock seizure (MES) model as indicated by a decrease in the extension/flexion ratio<sup>9</sup>.

Chemical examination of this plant revealed the presence of terpenoid ester, nardostachysin N, volatile, non-volatile constituents, sesquiterpenes coumarins, lignans, neolignans, alkaloids. Acacin, Ursolic acid, Octacosanol, Kanshone A, Nardosinonediol, Nardosinone, Aristolen-9beta-ol, Oleanolic acid, Beta-sitosterol are chemical constituents isolated from this plant<sup>10-12</sup>. The Discovery of the angiotensin-converting enzyme (ACE) leads to the drug discovery of anti-hypertensive drugs. The ACE converts angiotensin decapeptide inactive form into active octapeptide angiotensin II in the kidneys, especially in the renin-angiotensin-aldosterone system<sup>13</sup>. Captopril, Enalapril, Zofenopril, Ramipril, Fosinopril, Lisinopril, and SQ 29852 are the well-known ACE inhibitors<sup>13</sup>. Generally, Captopril is used as a positive control in most of the research study owing to its free radical scavenger activity that is highly relevant as an ACE inhibitor<sup>13</sup>.

	<p style="text-align: center;">DOI: 10.13040/IJPSR.0975-8232.12(5).2679-82</p>
	<p style="text-align: center;">This article can be accessed online on <a href="http://www.ijpsr.com">www.ijpsr.com</a></p>
<p>DOI link: <a href="http://dx.doi.org/10.13040/IJPSR.0975-8232.12(5).2679-82">http://dx.doi.org/10.13040/IJPSR.0975-8232.12(5).2679-82</a></p>	

Considering the above facts, the present study is aimed to conduct phytochemical screening and to examine the anti-hypertensive constituents present in rhizomes of *Nardostachys jatamansi*.

## MATERIALS AND METHODS:

**Plant Material:** *Nardostachys jatamansi* rhizomes were collected in the month of June 2016 from High Altitude Plant Physiology Research Centre, Srinagar [Gharwal] Uttarkhand, India. Rhizome was authenticated by comparing with the Herbarium (No. 2016/52) maintained at Department of Botany, J.S.S College Belagavi, Karnataka, India.

**Extraction:** The rhizomes were coarsely powdered in a pulverize with sieve # 16 in K.L.E Ayurveda Pharmacy, Shahapur, Belagavi, Karnataka, India. 100 g of each powdered material was subjected to Soxhlet extraction by using 400 mL of different solvents *viz.* dichloromethane, ethyl acetate, methanol, and water individually.

The extracted solution was dried individually under vacuum using a rotary vacuum evaporator and preserved in different amber-colored bottles.

**Phytochemical Screening:** The preliminary phytochemical screening was performed to characterize the various phytochemicals present in *Nardostachys jatamansi* rhizomes<sup>14</sup>. For instance, for the determination of alkaloids, Mayer's test, Hager's, and Dragendroff's test were performed.

Ferric chloride test was followed to identify tannins and phenolics. For the presence of glycosides, a Legal test was performed. An alkaline test was implemented to check flavonoids. Ninhydrin and Biuret test were followed to detect proteins. Steroids were checked through Salkowaski test. To test the presence of carbohydrates, Biuretic and Fehling's tests were employed.

**Fractionation and Purification:** Ethyl acetate extract was fractioned over silica gel column chromatography (60-120 mesh) under gradient elution of hexane and ethyl acetate (500 mL each) and methanol (500 mL) to provide dried fractions:

Fr.1 (10% ethyl acetate in hexane); Fr. 2 (25% ethyl acetate in hexane); Fr. 3 (50% ethyl acetate in hexane); Fr. 4 (75% ethyl acetate in hexane); Fr. 5 (100% ethyl acetate) and Fr. 6 (100% methanol).

**Angiotensin-Converting Enzyme [ACE] Inhibitory Assay:** Solvent extracts were subjected for anti-hypertensive activity by angiotensin-converting enzyme [ACE] inhibitory method with different concentrations of extract in comparison with a standard, captopril. ACE inhibition activity was carried out at BioGenics Labs, Hubli, Karnataka, India. ACE inhibition activity measured by a UV spectrophotometer based on the rate of formation of hippuric acid from hippuryl-L-histidyl-L-leusine (hhl) catalysed by ACE<sup>13</sup>.

Extracts were tested at 10, 50, and 100 µg dissolved in assay buffer (10mM) HEPES buffer containing 0.3 M NaCl and 10 µM zinc sulphate containing 20 µL kidney cortex plasma membranes (ACE enzyme source) and hippuryl-L-histidyl-L-leusine (hhl) as substrate. Briefly, the tested extracts are incubated at 37 °C for 10 min. Then the substrate is added, which makes a final reaction volume of 50 µL and incubated for 45 min at 37 °C. The reaction is terminated by the addition of 1M HCl. The yellow color is developed by the addition of 100 µL of pyridine and 50 µL of benzene sulphonyl chloride. The yellow color that formed is measured at 410 nm in an ELISA plate reader (iMark, BIORAD). Extracts with an inhibitory potential block the substrate availability to the enzyme and thereby cause enzyme inhibition leading to no formation of yellow color. The inhibition is represented in the form of percentage over control. Captopril, a standard, was tested at a concentration of 10, 15, and 25 nM. The rate of ACE inhibition was calculated by the formula,

$$\% \text{ Inhibition} = \frac{\Delta \text{ Control absorption} - \Delta \text{ Sample absorption}}{\Delta \text{ Sample absorption}}$$

**RESULTS AND DISCUSSION:** Preliminary phytochemical analysis showed that the occurrence of bioactive compounds such as alkaloids, flavonoids, carbohydrates, triterpenoid, glycosides, saponin, and tannins in different extracts **Table 1**.

ACE inhibition at 100 µg concentration follows the order: Ethyl acetate Extract (93.23%) > Water Extract (74.23%) > Dichloromethane Extract (67.03%) > Methanol Extract (56.77%). Among all the tested extracts, ethyl acetate extract has shown better result with 93% inhibition at 100 µg concentration as compared to other solvent


extracts. Captopril, a standard, was found to inhibit 85.37 % ACE at 25 nM.

Based on the ACE inhibition results, EtOAc extract was fractionated into six fractions: Fr. 1 (10% ethyl

acetate in hexane); Fr. 2 (25% ethyl acetate in hexane); Fr. 3 (50% ethyl acetate in hexane); Fr. 4 (75% ethyl acetate in hexane); Fr. 5 (100% ethyl acetate) and Fr. 6 (100% methanol) **Fig. 1**.

**TABLE 1: PHYTOCHEMICAL SCREENING OF EXTRACTS OF *NARDOSTACHYS JATAMANSI* RHIZOMES**


S. no.	Phytochemical Test	Dichloromethane	Ethyl Acetate	Methanol	Water
1	Alkaloids	+ ve	+ ve	+ ve	- ve
2	Tannins	+ ve	+ ve	+ ve	- ve
3	Saponins	+ ve	+ ve	+ ve	+ ve
4	Flavonoids	+ ve	+ ve	+ ve	+ ve
5	Carbohydrates	+ ve	+ ve	+ ve	+ ve
6	Glycosides	+ ve	+ ve	+ ve	+ ve
7	Steroids	+ ve	+ ve	+ ve	- ve



**FIG. 1: ACE INHIBITION ACTIVITY OF EXTRACTS OF *NARDOSTACHYS JATAMANSI* RHIZOMES.** Sample 1- Dichloromethane Extract (10, 50 and 100  $\mu\text{g}$ ); Sample 2-Ethyl acetate Extract (10, 50 and 100  $\mu\text{g}$ ); Sample 3-Methanol Extract (10, 50 and 100  $\mu\text{g}$ ); Sample 4-Water Extract (10, 50 and 100  $\mu\text{g}$ ); Sample 5-Captopril (10, 15 and 25 nM) (From Left to Right)

Six fractions of ethyl acetate extract were submitted for the ACE inhibition to identify the active constituent(s). Results revealed that Fr. 5 had shown significant inhibition at 100  $\mu\text{g}$  but no activity found at lower concentrations. Fr. 4 has shown a similar tendency, but inhibition at 100  $\mu\text{g}$  is less than Fr. 5. Fr. 3 has shown elevation in inhibitory activity at 50 and 100  $\mu\text{g}$ . The sample has shown little activity at 100  $\mu\text{g}$  whereas Fr. 1, 2 have not shown any inhibition at all concentrations screened, while captopril, a standard, was found to inhibit 85.37% ACE at 25 nM **Fig. 2**.

It is clearly evident from the ACE inhibition activity results **Fig. 1 & 2** of fractions of ethyl acetate extract of *Nardostachys jatamansi* rhizomes that there is a synergistic activity of constituents towards ACE inhibition. Among the tested extracts, ethyl acetate extract has shown prominent 93% inhibition at 100  $\mu\text{g}$  concentration. However, on purification of the ethyl acetate extract, ACE inhibition activity diminishes with only 19.03 to 47.35% inhibition for the purified fractions (Fr.1 to Fr.6).



**FIG. 2: ACE INHIBITION ACTIVITY OF FRACTIONS OF ETHYL ACETATE EXTRACT OF *NARDOSTACHYS JATAMANSI* RHIZOMES.** Fr.1 (10, 50 and 100  $\mu\text{g}$ ); Fr. 2 (10, 50 and 100  $\mu\text{g}$ ); Fr. 3 (10, 50 and 100  $\mu\text{g}$ ); Fr. 4 (10, 50 and 100  $\mu\text{g}$ ); Fr. 5 (10, 50 and 100  $\mu\text{g}$ ); Fr. 6 (10, 50 and 100  $\mu\text{g}$ ); Captopril (10, 15 and 25 nM) (From Left to Right)

**CONCLUSION:** The present study was designed to examine the anti-hypertensive constituents present in *Nardostachys jatamansi*. Among all the tested extracts, ethyl acetate extract was found to be active against ACE inhibition. However, ACE inhibition was found to diminishes significantly on further purification of ethyl acetate extract. This suggested that potent molecules are present in ethyl acetate that works in synergistic combination and

justify the use of *Nardostachys jatamansi* for treatment of hypertension-related disorders.

**ACKNOWLEDGEMENT:** Authors are thankful to Dr. U. V. Babu (Head), Dr. Neeraj K. Patel (Research Scientist), and Sharath Kumar L. M. (Research Scientist), Phytochemistry Division, The Himalaya Drug Company, Bangalore, India,

Dr. Sanjay Mishra Scientist Grade II, Prabhakar Kore Basic Science Research Centre, Belagavi for carrying out part of this research work and for fruitful discussion.

**CONFLICTS OF INTEREST:** The authors declare no competing financial interest exists.

#### REFERENCES:

1. Ali S, Ansari KA, Jafry MA, Kabeer H and Diwakar G: *Nardostachys jatamansi* protects against liver damage induced by thioacetamide in rats. *Journal of Ethnopharmacology* 2000; 71: 359-63.
2. Arora RB and Madan BR: Antiarrhythmics. III. Antiarrhythmic activity of *Nardostachys jatamansi* (an Indian indigenous drug). *Indian Journal of Medical Research* 1956; 44: 259-69.
3. Arora RB, Sharma PL and Kapila K: Anti-arrhythmic and anticonvulsant activity of *jatamansi*. *Indian Journal of Medical Research* 1958; 46: 782-91.
4. Arora RB, Singh KP, Das PK and Mistry PN: Prolonged hypotensive effect of the essential of *N. jatamansi*. *Archives Internationales de Pharmacodynamie et de Therapie* 1958; 113: 367-76.
5. Dhiman N and Bhattacharya A: *Nardostachys jatamansi* (D.Don) DC.-Challenges and opportunities of harnessing the untapped medicinal plant from the Himalayas. *Journal of Ethnopharmacology* 2020; 246: 112211.
6. Joglekar N and Barve S: Standardization, validation and elementary phytochemical screening of Valerian and *Nardostachys*. *International Journal of Recent Scientific Research* 2019; 10: 33939-42.
7. Arora P, Arora V and Singh MP: Pharmacognostic standardisation of medicinally important *Nardostachys jatamansi*. *World Journal of Pharmacy and Pharmaceutical Sciences* 2017; 6: 834-49.
8. Kasar PI, Kirte Mc and Ukey R: Effect of *Jatamansi (Nardostachys Jatamansi)* on blood pressure in Rajonivritti Kala (Menopause). *World Journal of Pharmacy and Pharmaceutical Sciences* 2018; 7: 834-41.
9. Chatterjee A: *The Treatise on Indian Medical Plants*; National Institute of Science Communication, New Delhi, 1997.
10. Tabassum K, Shafi M and Sofi G: Efficacy of Sumbul ut Teeb (*Nardostachys jatamansi* Linn) on vasomotor symptoms in post menopausal women-an open observational study. *EC Clinical and Medical Case Reports* 2019; 01-09.
11. Razack S, Kandikattu HK, Venuprasad MP, Amruta N, Khanum F, Chuttani K and Mishra AK: Anxiolytic actions of *Nardostachys jatamansi* GABA benzodiazepine channel complex mechanism and its biodistribution studies. *Metabolic Brain Disease* 2018; 33: 1533-49.
12. Chatterjee A, Basak B, Saha M, Dutta U, Mukhopadhyay C and Banerji J: Structure and Stereochemistry of *nardostachysin*; a new terpenoid ester constituent of the rhizomes of *Nardostachys jatamansi*. *Journal of Natural Products* 2000; 63: 1531-33.
13. Ahmad I, Yanuar, A, Mulia, K and Mun'im A: Review of angiotensin-converting enzyme inhibitory assay: rapid method in drug discovery of herbal plants. *Pharmacognosy Reviews* 2017; 11: 1-7.
14. Banu KS and Cathrine L: General Techniques involved in Phytochemical Analysis. *International Journal of Advanced Research in Chemical Science* 2015; 2: 25-32.

#### How to cite this article:

Rachotimath BB, Gavimath MS and Padmashali B: Antihypertensive activity guided-fractionation of *Nardostachys jatamansi*. *Int J Pharm Sci & Res* 2021; 12(5): 2679-82. doi: 10.13040/IJPSR.0975-8232.12(5).2679-82.

All © 2013 are reserved by the International Journal of Pharmaceutical Sciences and Research. This Journal licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

This article can be downloaded to **Android OS** based mobile. Scan QR Code using Code/Bar Scanner from your mobile. (Scanners are available on Google Playstore)